Literature DB >> 29107148

Amino acid misincorporation in recombinant proteins.

H Edward Wong1, Chung-Jr Huang1, Zhongqi Zhang2.   

Abstract

Proteins provide the molecular basis for cellular structure, catalytic activity, signal transduction, and molecular transport in biological systems. Recombinant protein expression is widely used to prepare and manufacture novel proteins that serve as the foundation of many biopharmaceutical products. However, protein translation bioprocesses are inherently prone to low-level errors. These sequence variants caused by amino acid misincorporation have been observed in both native and recombinant proteins. Protein sequence variants impact product quality, and their presence can be exacerbated through cellular stress, overexpression, and nutrient starvation. Therefore, the cell line selection process, which is used in the biopharmaceutical industry, is not only directed towards maximizing productivity, but also focuses on selecting clones which yield low sequence variant levels, thereby proactively avoiding potentially inauspicious patient safety and efficacy outcomes. Here, we summarize a number of hallmark studies aimed at understanding the mechanisms of amino acid misincorporation, as well as exacerbating factors, and mitigation strategies. We also describe key advances in analytical technologies in the identification and quantification of sequence variants, and some practical considerations when using LC-MS/MS for detecting sequence variants.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Amino acid misincorporation; Biopharmaceuticals; CHO; E. coli; LC-MS/MS; Mass spectrometry; Sequence variant analysis

Mesh:

Substances:

Year:  2017        PMID: 29107148     DOI: 10.1016/j.biotechadv.2017.10.006

Source DB:  PubMed          Journal:  Biotechnol Adv        ISSN: 0734-9750            Impact factor:   14.227


  8 in total

1.  Expression vector-derived heterogeneity in a therapeutic IgG4 monoclonal antibody.

Authors:  Douglas S Rehder; Chris J Wisniewski; Denfeng Liu; Diya Ren; Dell Farnan; Matthew R Schenauer
Journal:  MAbs       Date:  2018-11-07       Impact factor: 5.857

2.  Identification and characterization of an IgG sequence variant with an 11 kDa heavy chain C-terminal extension using a combination of mass spectrometry and high-throughput sequencing analysis.

Authors:  Claire Harris; Weichen Xu; Luigi Grassi; Chunlei Wang; Abigail Markle; Colin Hardman; Richard Stevens; Guillermo Miro-Quesada; Diane Hatton; Jihong Wang
Journal:  MAbs       Date:  2019-10-01       Impact factor: 5.857

3.  An evaluation of instrument types for mass spectrometry-based multi-attribute analysis of biotherapeutics.

Authors:  Zhongqi Zhang; Pik K Chan; Jason Richardson; Bhavana Shah
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857

4.  Characterization of light chain c-terminal extension sequence variant in one bispecific antibody.

Authors:  Jun Lin; Mengyu Xie; Dan Liu; Zhen Gao; Xiaoyan Zhao; Hongxia Ma; Sheng Ding; Shu Mei Li; Song Li; Yanling Liu; Fang Zhou; Hao Hu; Tao Chen; He Chen; Min Xie; Bo Yang; Jun Cheng; Mingjun Ma; Yanyang Nan; Dianwen Ju
Journal:  Front Chem       Date:  2022-09-20       Impact factor: 5.545

5.  Identification, characterization and control of a sequence variant in monoclonal antibody drug product: a case study.

Authors:  Anushikha Thakur; Rekha Nagpal; Avik Kumar Ghosh; Deepak Gadamshetty; Sirisha Nagapattinam; Malini Subbarao; Shreshtha Rakshit; Sneha Padiyar; Suma Sreenivas; Nagaraja Govindappa; Harish V Pai; Ramakrishnan Melarkode Subbaraman
Journal:  Sci Rep       Date:  2021-06-24       Impact factor: 4.379

6.  Broad range of missense error frequencies in cellular proteins.

Authors:  Raffaella Garofalo; Ingo Wohlgemuth; Michael Pearson; Christof Lenz; Henning Urlaub; Marina V Rodnina
Journal:  Nucleic Acids Res       Date:  2019-04-08       Impact factor: 16.971

Review 7.  Evolution of a comprehensive, orthogonal approach to sequence variant analysis for biotherapeutics.

Authors:  T Jennifer Lin; Kathryn M Beal; Paul W Brown; Heather S DeGruttola; Mellisa Ly; Wenge Wang; Chia H Chu; Robert L Dufield; Gerald F Casperson; James A Carroll; Olga V Friese; Bruno Figueroa; Lisa A Marzilli; Karin Anderson; Jason C Rouse
Journal:  MAbs       Date:  2018-10-25       Impact factor: 5.857

8.  A general evidence-based sequence variant control limit for recombinant therapeutic protein development.

Authors:  Aming Zhang; Zhengwei Chen; Meinuo Li; Haibo Qiu; Shawn Lawrence; Hanne Bak; Ning Li
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.